Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Dr. Suneel Kamath, a gastrointestinal medical oncologist at Cleveland Clinic in Ohio and an assistant professor of medication on the Cleveland Clinic...
For sufferers residing with metastatic colorectal most cancers whose illness has progressed after commonplace chemotherapy, remedy choices may be restricted and outcomes...
New real-world proof means that remedy alternative might make a significant distinction for sufferers dwelling with metastatic castration-sensitive prostate most cancers (mCSPC),...
